Knockdown of Akt sensitizes osteosarcoma cells to apoptosis induced by cisplatin treatment

International Journal of Molecular Sciences

Volumn 12, Issue 5, 2011, Pages 2994-3005

  Zhang, Guoyou ^a   Li, Ming ^a   Zhu, Xiaodong ^a   Bai, Yushu ^a   Yang, Changwei ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Akt; Apoptosis; Chemotherapy; Cisplatin; Osteosarcoma; Puma

Indexed keywords

CISPLATIN; PROTEIN AKT1; PROTEIN AKT3; PROTEIN KINASE; PROTEIN KINASE B; PROTEIN KINASE B BETA; PUMA PROTEIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; AKT2 PROTEIN, HUMAN; ANTINEOPLASTIC AGENT; APOPTOSIS REGULATORY PROTEIN; BBC3 PROTEIN, HUMAN; ONCOPROTEIN; PROTEIN P53;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CULTURE; CELL SURVIVAL; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG CYTOTOXICITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; OSTEOSARCOMA CELL; PROTEIN EXPRESSION; UPREGULATION; WESTERN BLOTTING; CELL PROLIFERATION; DRUG EFFECTS; GENE SILENCING; GENETICS; METABOLISM; OSTEOSARCOMA; PATHOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE KNOCKDOWN TECHNIQUES; HUMANS; OSTEOSARCOMA; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; TUMOR SUPPRESSOR PROTEIN P53;

EID: 79957815223     PISSN: None     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms12052994     Document Type: Article

References (20)

1. Mirabello, L.; Troisi, R.J.; Savage, S.A. Osteosarcoma incidence and survival rates from 1973 to 2004: Data from the Surveillance, Epidemiology, and End Results Program. Cancer 2009, 115, 1531-1543.
2. Ferrari, S.; Briccoli, A.; Mercuri, M.; Bertoni, F.; Picci, P. Postrelapse survival in osteosarcoma of the extremities: Prognostic factors for long-term survival. J. Clin. Oncol. 2003, 21, 710-715.
3. Ferrari, S.; Smeland, S.; Mercuri, M.; Bertoni, F.; Longhi, A. Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate,cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: A joint study by the Italian and Scandinavian Sarcoma Groups. J. Clin. Oncol. 2005, 23, 8845-8852.
4. Kandel, E.S.; Hay, N. The regulation and activities of the multifunctional serine/threonine kinase Akt/PKB. Exp. Cell Res. 1999, 253, 210-229.
5. Brazil, D.P.; Hemmings, B.A. Ten years of protein kinase B signalling: A hard Akt to follow. Trends Biochem. Sci. 2001, 26, 657-664
6. Cantrell, D.A. Phosphoinositide 3-kinase signaling pathways. J. Cell Sci. 2001, 114, 1439-1445.
7. Jeffers, J.R.; Parganas, E.; Lee, Y. Puma is an essential mediator of p53-dependent and independent apoptotic pathways. Cancer Cell 2003, 4, 321-328.
8. Villunger, A.; Michalak, E.M.; Coultas, L. p53-and drug-induced apoptotic responses mediated by BH3-only proteins puma and noxa. Science 2003, 302, 1036-1038.
9. Zhang, K.J.; Chen, D.; Wang, X.G.; Zhang, S.Y.; Wang, J.G.; Gao, Y.; Yan, B.M. RNA Interference targeting Slug increases cholangiocarcinoma cell Sensitivity to Cisplatin via upregulating PUMA. Int. J. Mol. Sci. 2011, 12, 385-400.
10. Karst, A.M.; Dai, D.L.; Cheng, J.Q.; Li, G. Role of p53 up-regulated modulator of apoptosis and phosphorylated akt in melanoma cell growth, apoptosis, and patient survival. Cancer Res. 2006, 66, 9221-9226.
11. Katome, T.; Obata, T.; Matsushima, R.; Masuyama, N.; Cantley, L.C.; Gotoh, Y.; Kishi, K.; Shiota, H.; Ebina, Y. Use of RNA interference-mediated gene silencing and adenoviral overexpression to elucidate the roles of AKT/protein kinase B isoforms in insulin actions. J. Biol. Chem. 2003, 278, 28312-28323.
12. Senthivinayagam, S.; Mishra, P.; Paramasivam, S.K.; Yallapragada, S.; Chatterjee, M.; Wong, L.; Rana, A.; Rana, B. Caspase-mediated cleavage of beta-catenin precedes drug-induced apoptosis in resistant cancer cells. J. Biol. Chem. 2009, 284, 13577-13588.
13. Arlt, A.; Gehrz, A.; Müerköster, S.; Vorndamm, J.; Kruse, M.L.; Fölsch, U.R.; Schäfer, H. Role of NF-kappaB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death. Oncogene 2003, 22, 3243-3251.
14. Bader, A.G.; Kang, S.; Zhao, L.; Vogt, P.K. Oncogenic PI3K deregulates transcription and translation. Nat. Rev. Cancer 2005, 5, 921-929.
15. Cardone, M.H.; Roy, N.; Stennicke, H.R.; Salvesen, G.S.; Franke, T.F.; Stanbridge, E.; Frisch, S.; Reed, J.C. Regulation of cell death protease caspase-9 by phosphorylation. Science 1998, 282, 1318-1321.
16. Datta, S.R.; Dudek, H.; Tao, X.; Masters, S.; Fu, H.; Gotoh, Y.; Greenberg, M.E. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997, 91, 231-241.
17. del Peso, L.; Gonzalez-Garcia, M.; Page, C.; Herrera, R.; Nunez, G. Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science 1997, 278, 687-689.
18. Jones, R.G.; Parsons, M.; Bonnard, M.; Chan, V.S.; Yeh, W.C.; Woodgett, J.R.; Ohashi, P.S. Protein kinase B regulates T lymphocyte survival, nuclear factor kappaB activation, and Bcl-X(L) levels in vivo. J. Exp. Med. 2000, 191, 1721-1734.
19. Jiang, M.; Wei, Q.; Wang, J.; Du, Q.; Yu, J.; Zhang, L.; Dong, Z. Regulation of PUMA-a by p53 in cisplatin-induced renal cell apoptosis. Oncogene 2006, 25, 4056-4066.
20. Fraser, M.; Bai, T.; Tsang, B.K. Akt promotes cisplatin resistance in human ovarian cancer cells through inhibition of p53 phosphorylation and nuclear function. Int. J. Cancer 2008, 122, 534-546.